Quick Answer
Gossamer Bio, Inc. reported Long Term Debt of $0.00 for the year ending 2024.
- Gossamer Bio, Inc. showed a decrease of -100.0% in Long Term Debt from 2023 to 2024.
- This data is from Gossamer Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2025.
- XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $28.28 million | Q3 2019: $28.37 million | Q1 2020: $28.55 million | Q2 2020: $28.64 million | Q3 2020: $28.67 million | Q1 2021: $28.82 million | Q2 2021: $28.91 million | Q3 2021: $28.99 million | Q1 2022: $29.17 million | Q2 2022: $17.65 million | Q3 2022: $14.83 million | Q1 2023: $9.22 million | Q2 2023: $6.44 million | Q3 2023: $3.63 million | Q1 2024: $0.00 | Q2 2024: $0.00 | Q3 2024: $0.00.
- Over the full 6 years of available data (2019 to 2024), Gossamer Bio, Inc.'s Long Term Debt has declined by 100.0%.
- Historical annual values: Fiscal year 2024: $0.00 | Fiscal year 2023: $814.0 thousand | Fiscal year 2022: $11.99 million | Fiscal year 2021: $29.08 million | Fiscal year 2020: $28.74 million | Fiscal year 2019: $28.46 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: